



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,427	05/10/2005	Hans-Georg Capraro	ON/4-32759A	5061
1095 7550 11/14/2007				
NOVARTIS				
CORPORATE INTELLECTUAL PROPERTY				
ONE HEALTH PLAZA 104/3				
EAST HANOVER, NJ 07936-1080				
EXAMINER				
MOORE, SUSANNA				
ART UNIT		PAPER NUMBER		
1624				
MAIL DATE		DELIVERY MODE		
11/14/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/534,427

Applicant(s)

CAPRARO ET AL.

Examiner

Susanna Moore

Art Unit

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 October 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-9 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-946)
- 3) ☒ Information Disclosure Statement(s) (PTO/SI/02)
Paper No(s)/Mail Date 12/8/05
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Election/Restrictions

Applicant's election of Group (I), claims 1-9, in the reply filed on 10/15/2007 is acknowledged. The traversal was not addressed and as such will be treated as not being traversed.

The requirement is deemed proper and is therefore made **FINAL**.

In summary, claims 1-9 are currently pending and claims 10-12 are cancelled.

Information Disclosure Statement

The information disclosure statement filed 12/8/2005 fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It has been placed in the application file, but the information referred to therein has not been considered. Some of the documents are missing.

Claim Objections

Claim 8 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. The recitation of an intended use, chemical activity or functional

Art Unit: 1624

description of some "additional" property for a compound (or moiety/functionality attached to the chemical core) or composition containing same in dependent claim, must result in a tangible structural difference between the product of the independent claim and the product set forth in the dependent claim. In the absence of said structural difference between the product of the independent claim and that of the dependent claim, said dependent claim is seen to be a substantial duplicate, and the said recitation is not afforded critical weight and fails to further limit the product in said dependent claim.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Throughout the claims, Applicant employs the terms "unsubstituted or substituted." On pages 3-5 of the Specification, there is a discussion of the concept of substitution. However, this passage fails to list the intended substituents. A number of examples are given using open terms. What other substituents is Applicant claiming? Where applicant acts as his or her own lexicographer to specifically define a term of a claim contrary to its ordinary meaning, the

written description must clearly redefine the claim term and set forth the uncommon definition so as to put one reasonably skilled in the art on notice that the applicant intended to so redefine that claim term. *Process Control Corp. v. HydReclaim Corp.*, 190 F.3d 1350, 1357, 52 USPQ2d 1029, 1033 (Fed. Cir. 1999).

Applicants have defined R² as “a heterocyclic radical” but apparently, Applicant intends “optionally substituted heterocyclic radical” as seen by the named substituents in dependent claim 6. Applicant should put in “substituted” for any groups for which they intend as substituted alkyl.

Claims 1-9 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In evaluating the enablement question, several factors are to be considered. *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988); *Ex parte Forman*, 230 USPQ 546. The factors include: 1) The nature of the invention, 2) the state of the prior art, 3) the predictability or lack thereof in the art, 4) the amount of direction or guidance present, 5) the presence or absence of working examples, 6) the breadth of the claims, and 7) the quantity of experimentation needed.

HOW TO MAKE: The nature of the invention in the instant case, has claims, which embrace a wide range of chemically and physically distinct compounds, wherein X-R⁴ are a variety of variables with working examples only to X= oxygen and R⁴= benzyl. The exact nature

Art Unit: 1624

of these substituents are vague and indefinite in that it is not clear exactly how to make the compounds of the instant invention where there is more than the above-mentioned substituents on the phenyl ring. While many specific examples are disclosed, there is insufficient guidance for preparing the compounds where $X-R^4$ are not O-benzyl.

Patent Protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable. Tossing out the mere germ of an idea does not constitute enabling disclosure. *Genentech Inc. v. Novo Nordisk* 42 USPQ2d 1001.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hirst et. al. (U.S. 6,713,474).

The instant invention claims compounds of formula (I), wherein R^1 = hydrogen, R^2 = 4-methylpiperazinyl, X = oxygen and R^4 = benzyl and X- R^4 is at the 3 position of the phenyl ring.

The reference teaches a compound of formula (I), wherein R^1 = hydrogen, R^2 = 4-methylpiperazinyl, X = oxygen and R^4 = benzyl. See column 130, lines 53-55. Another species found in the reference is a compound of formula (I), wherein R^1 = hydrogen, R^2 = 4-methylpiperazinyl, X = oxygen and R^4 = benzyl and X- R^4 is at the 4 position of the phenyl ring.. See column 130, lines 53-55.

The difference between the claimed compound and the reference is the position of the X- R^4 on the phenyl ring, the 4 position versus Applicant's 3 position. The MPEP 2144.09 states "Compounds which are position isomers (compounds having the same radicals in physically different positions on the same nucleus)... are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977).

Moreover, the generic structure of Hirst encompasses the instantly claimed compounds (see Formula I, column 9) as claimed herein. Columns-9-12, define the substituents as follows: R¹ is hydrogen, substituted or unsubstituted aliphatic group, halogen; R² is substituted or unsubstituted cycloalkyl group, etc.; X= O, NH, S; and R⁴ is substituted or unsubstituted aralkyl group, substituted or unsubstituted heteroaralkyl group, etc. The compounds of the instant invention are generically embraced by Hirst in view of the interchangeability of the substitutions of the pyrrolo[2,3-d]pyrimidine. Thus, one of ordinary skill in the art at the time the invention was made would have been motivated to select for example NHCH₂phenyl for X-R⁴ as well as other possibilities from the generically disclosed alternatives of the reference and in so doing obtain the instant compounds in view of the equivalency teachings outlined above.

The same arguments applied above can be directed towards the following references: U.S. 2003175935, 2003082622, 2003153752; WO 2001072751 and 2000017202. These references have the same species listed above in the art rejection. The references also teach genus equivalency teachings of the substituents.

Double Patenting

No obviousness-type double patenting rejection over co-pending application 10/477594 is not being made because there is no incidental overlap in the claims. The co-pending application claims compounds of formula (I), wherein a cyclobutyl group is found on the nitrogen at the 8 position of the pyrrolopyrimidine scaffold, whereas the instant case is drawn to

compounds of formula (I), wherein a cyclohexyl group is substituted on the nitrogen at the 8 position of the pyrrolopyrimidine scaffold. However, there are no species or guideposts being claimed in the co-pending application that are being claimed in the instant application. Thus, the obviousness-type double patenting was considered but not applied.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susanna Moore whose telephone number is (571) 272-9046. The examiner can normally be reached on M-F 8:00-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1624

/Susanna Moore/

Examiner, Art Unit 1624

/Brenda L. Coleman/

Primary Examiner, Art Unit 1624